Faculty Information - NEMOTO Yuuki

（Last updated : 2025-06-03 10:28:59）

NEMOTO Yuuki
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Research Associate

■ Published papers

1.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
2.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
3.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
4.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
5.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
6.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
7.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
8.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
9.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/07
10.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
11.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
12.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
13.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
14.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
15.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
16.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
17.	Original article	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
18.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
19.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
20.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
21.	Original article	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
22.	Original article	The controlling nutritional status CONUT score in patients with advanced bladder cancer after radical cystectomy. 2021/03
23.	Original article	The experience of kidney transplantation in patients with antiphospholipid syndrome. 2020/12/10
Display 5 items
Display all(23)

■ Academic conference presentation

1.	Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. （Poster notice，General） 2025/04/29
2.	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. （Poster notice，General） 2025/04/28
3.	Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors. （Poster notice，General） 2025/04/28
4.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
5.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （Poster notice） 2024/04/27
6.	Therapeutic efficacy of Cabozantinib or Axitinib rechallenge for advanced renal cell carcinoma. （Poster notice，General） 2024/04/27
7.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （Poster notice） 2024/04/26
8.	Clinical study of RAPN between RENAL Nephrometry Score 2-2-3-3 and 1-3-3-3. （Poster notice，General） 2024/04/26
9.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （Poster notice） 2024/04/26
10.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （Poster notice） 2024/04/26
11.	The retrospective study of upfront cytoreductive nephrectomy for metastatic renal cell carcinoma. （Poster notice，General） 2024/04/25
12.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （Poster notice，General） 2023/04/29
13.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （Poster notice，General） 2023/04/29
14.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （Speech，General） 2023/04/20
15.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （Poster notice，General） 2022/05/13
16.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （Poster notice，General） 2022/05/13
17.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
18.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
19.	Association between controlling nutritional status（CONUT）score and outcomes after radical cystectomy for advanced bladder cancer. （Speech，General） 2020/12/23
Display 5 items
Display all(19)